ASCO: Regeneron Shows Early Bispecific Antibody Efficacy In Hard-To-Treat Colorectal Cancer

Scrip talked to Regeneron at ASCO about REGN7075 and Regeneron’s bispecific development strategy in solid tumors.

• Source: Scrip

More from ASCO

More from Conferences